SUMMARY: Macrolide-resistant Mycoplasma pneumoniae is emerging in several countries, and it is mainly observed in children. To our knowledge, we conducted the first multicenter prospective epidemiological study of macrolide-resistant M. pneumoniae in order to investigate regional differences in the susceptibility of macrolide-resistant M. pneumoniae to antibacterial agents. The in vitro activities of 11 antimicrobial agents against macrolide-resistant M. pneumoniae isolates from 5 different areas of Japan were investigated. Among 190 M. pneumoniae isolates from pediatric patients, 124 (65.2z) isolates showed macrolide resistance and possessed an A2063G transition in domain V of the 23S rRNA. These isolates showed high resistance to erythromycin, clarithromycin, and azithromycin with minimum inhibitory concentrations (MICs) AE16 mg/ml. Conversely, quinolones such as garenoxacin, moxifloxacin, tosufloxacin, and levofloxacin exhibited potent antimycoplasmal activity. No regional differences were observed with respect to the MICs among the 5 areas in Japan.
Mycoplasma pneumoniae is a major causative pathogen of respiratory tract infections, and it is found mainly in children and younger adults. Although the 14-and 15-membered macrolides are generally considered as the first-choice agents against M. pneumoniae infections in children, it has been reported that more than 40z of M. pneumoniae isolates are resistant to macrolides in Japan (1, 2) . Macrolide-resistant M. pneumoniae is also emerging in several other countries, primarily in children (3) (4) (5) (6) (7) (8) (9) . During an outbreak of M. pneumoniae infections in Italy in 2010, 11 (25.5z) of the 43 hospitalized pediatric patients with M. pneumoniae were macrolide resistant (4) . In particular, the reported incidence of macrolide-resistant M. pneumoniae is more than 90z in China (6) . Thus, the increasing resistance of M. pneumoniae to commonly used 14-and 15-membered macrolides is a growing concern.
Specific point mutations in domain V of the 23S rRNA gene of M. pneumoniae define the macrolideresistant phenotypes. The mutations that induce a high level of macrolide resistance are an A to G transition at position 2063 and an A to C transition at position 2064; whereas, low-level resistance is induced by a C to A or G transition at position 2617 and an A to T transition at position 2063 (1, 9) . All of the macrolide-resistant M.
pneumonia isolates had mutations in domain V of the 23S rRNA gene (1, 2, 10, 11) . Several studies indicated that macrolide resistance in M. pneumoniae may have clinical significance in terms of diminished response to treatment with drugs in this class (2, 12, 13) . In Japan, reports of macrolide-resistant M. pneumoniae were from limited areas, and there have been no large-scale epidemiological studies conducted throughout Japan. The purpose of the present study was to investigate regional differences in the susceptibility of macrolideresistant M. pneumoniae to antibacterial agents. Thus, to our knowledge, this is the first multicenter prospective epidemiological study of macrolide-resistant M. pneumoniae.
We enrolled all pediatric patients with acute respiratory tract infections who visited 62 institutions located in 5 areas of Japan (20 institutions in Kyushu, 25 in Chugoku, 3 in Shikoku, 11 in Kinki, and 3 in Hokkaido), participating in the Atypical Pathogen Study Group from November 2009 to August 2011 (Fig. 1) . Pediatricians at the facilities collected samples from patients with suspected M. pneumoniae infections. Informed consent was obtained from the parents of all patients. The Ethics Committee at Kawasaki Medical School approved the study protocol.
M. pneumoniae isolates were obtained by cultivation of specimens. The medium used for isolation and determination of the minimum inhibitory concentration (MIC) was pleuropneumonia-like organism broth (PPLO; Oxoid, Franklin, N.J., USA) supplemented with 0.5z glucose (Wako Pure Chemicals Inc., Osaka, Japan), 20z Mycoplasma supplement-G (Oxoid), and 0.0025z phenol red (Sigma-Aldrich Co. LLC., St. Louis, Mo., USA). The MICs of the 11 antimicrobial agents for the isolates were determined by micro-dilution methods (14) . Briefly, medium containing 10 5 -10 6 CFU/ml of M. pneumoniae was placed in 96-well microplates and incubated at 379 C for 6-8 days. The MIC was defined as the lowest concentration of antimicrobial agents at which the metabolism of the organism was inhibited as evidenced by a lack of color change in the medium when the drug-free control first showed a color. Reference strain FH was used as drug-susceptible control. The antimicrobial agents used for MIC determination were as follows: erythromycin, clarithromycin, azithromycin, rokitamycin, clindamycin, minocycline, tetracycline, tosufloxacin, garenoxacin, levofloxacin, and moxifloxacin.
Specific point mutations in domain V of the 23S rRNA gene of M. pneumoniae define the macrolideresistance phenotypes. We performed full-length sequencing of the 23S rRNA gene in M. pneumoniae isolates showing macrolide resistance, as reported previously (11) .
Statistical analysis was performed using Stat View version 5.0. (SAS Institute Inc., Cary, N.C., USA). The number of patients per gender and disease classification was compared using the Fisher's exact test. We used the Wilcoxon rank-sum test to compare the mean age of patients. P values less than 0.05 were statistically significant.
A total of 190 (18.4z) isolates of M. pneumoniae were obtained by cultivation of samples from 1,032 pediatric patients with respiratory tract infections (37 samples were obtained in Kyushu, 73 in Chugoku, 19 in Shikoku, 20 in Kinki, and 41 in Hokkaido) ( Table 1) . Of the 190 isolates, 124 (65.2z) were classified as macrolide-resistant M. pneumoniae by genetic analysis, and all had the point mutation A2063G in domain V of the 23S rRNA gene. Patient characteristics are shown in Table 2 . There were no statistically significant differences in terms of age, gender, or disease classification between the macrolide-resistant and macrolide-sensitive M. pneumoniae groups. Table 3 shows the MIC range, MIC 50 , and MIC 90 for the 11 agents according to the presence or absence of a mutation in the 23S rRNA gene in the 190 M. pneumoniae isolates. Among the 124 isolates that were with macrolide resistant, the MIC 50 and MIC 90 values for 14-and 15-membered macrolides (e.g., erythromycin, clarithromycin, and azithromycin) were 64 mg/ml to À128 mg/ml and 128 mg/ml to À128 mg/ml, respectively. Compared to the 14-and 15-membered macrolides, the 16-membered macrolide, rokitamycin, had moderate-level resistance, with MIC 50 and MIC 90 values of 0.25 mg/ml and 0.5 mg/ml, respectively. Higher MIC values are reported for rokitamycin in the other mutations such as A2064G and A2063C in domain V of the 23S rRNA gene (1) . Conversely, all quinolones, especially garenoxacin and moxifloxacin, showed excellent antimycoplasmal activity, with MIC 50 values of 0.0313 mg/ml and 0.0625 mg/ml, respectively, and MIC 90 values of 0.0625 mg/ml and 0.125 mg/ml, respectively, against macrolide-resistant M. pneumoniae isolates; these values were equal to that against macrolide-sensitive M. pneumoniae isolates. Tosufloxacin, the only quinolone approved for treatment of pneumonia in pediatric patients in Japan, also showed good antimycoplasmal activity against the macrolide-resistant isolates. The MIC 50 and MIC 90 values were 0.25 mg/ml and 0.5 mg/ml, respectively. There were no regional differences among the 5 areas in Japan with respect to the MIC values.
A2063G in domain V of the 23S rRNA is the most frequent mutation association with macrolide resistance, followed by A2064G. The A2063C, C2617G, C2617A, and A2063T mutations are rare (1,2,9 ). All macrolideresistant isolates in the present study had the same mu- The optimal treatment for serious infection caused by macrolide-resistant M. pneumoniae remains unclear. In healthy children with severe infections caused by macrolide-resistant M. pneumoniae, ciprofloxacin showed a favorable clinical and microbiological response without any adverse effects (3, 15) . The 2011 version of the Japanese guidelines for the management of respiratory infectious diseases in children recommends the use of tosufloxacin instead of macrolides when a macrolideresistant M. pneumoniae infection is suspected (16) . Tosufloxacin, a fluoroquinolone antimicrobial agent that has been reported to have a broader spectrum and potent activity against Gram-positive and Gram-negative bacteria including M. pneumoniae, has been approved for the treatment of pneumonia in pediatric patients since 2010 (17, 18) . In our study, tosufloxacin showed good in vitro activity against clinical isolates of M. pneumoniae, both with or without the A2063G mutation. Further, we demonstrated that the number of M. pneumoniae isolates in the nasopharynx of patients with macrolide-resistant M. pneumoniae decreased promptly after treatment with tosufloxacin for 48 h, and this was found to be related to the clinical outcome (19) . To investigate the clinical efficacy of tosufloxacin against macrolide-resistant M. pneumoniae strains, multicenter clinical trials will be needed. After tosufloxacin obtained authority's approval of indication, guidelines should recommend the use of tosufloxacin for the treatment of macrolide-resistant M. pneumoniae strains. Furthermore, physicians should select antibiotics based on the pharmacokinetics/pharmacodynamics. A nationwide surveillance may provide important information regarding empirical therapy against M. pneumoniae infections.
